Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
cy6463 save search
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
Published: 2022-08-09 (Crawled : 20:00) - ir.cyclerion.com
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: 2.67%
H: 5.59%
C: -1.58%
cy6463 results
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
Published: 2022-07-28 (Crawled : 11:00) - ir.cyclerion.com
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: 0.0%
H: 22.08%
C: 22.08%
cy6463 topline schizophrenia therapeutics positive
Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
Published: 2022-06-28 (Crawled : 13:00) - ir.cyclerion.com
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: 8.39%
H: 0.32%
C: -7.82%
cy6463 disease therapeutics positive
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
Published: 2022-06-22 (Crawled : 13:00) - ir.cyclerion.com
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: -0.5%
H: 9.6%
C: 1.4%
cy6463 disease therapeutics
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
Published: 2022-06-17 (Crawled : 12:00) - ir.cyclerion.com
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: 7.81%
H: 6.0%
C: -5.66%
cy6463 disease preclinical therapeutics pre-clinical
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
Published: 2022-06-10 (Crawled : 11:00) - ir.cyclerion.com
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: -20.73%
H: 0.0%
C: 0.0%
cy6463 topline symposium therapeutics positive
Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium
Published: 2022-06-06 (Crawled : 11:00) - ir.cyclerion.com
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: 10.87%
H: 5.5%
C: -2.06%
cy6463 preclinical topline symposium therapeutics pre-clinical
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
Published: 2022-05-04 (Crawled : 16:20) - ir.cyclerion.com
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: 11.24%
H: 0.0%
C: -14.95%
cy6463 results
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
Published: 2022-02-24 (Crawled : 16:20) - ir.cyclerion.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 3.94%
H: 0.0%
C: 0.0%
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: 0.4%
H: 3.0%
C: -3.87%
cy6463 ces
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
Published: 2022-01-26 (Crawled : 14:00) - biospace.com/
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: 0.81%
H: 6.4%
C: -4.0%
cy6463 alzheimer phase 2 therapeutics disease alzheimer’s alzheimer's disease alzheimer's phase 2b
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment
Published: 2021-09-22 (Crawled : 15:00) - biospace.com/
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: 2.47%
H: 6.93%
C: -2.11%
disease preclinical cy6463 pre-clinical train
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)
Published: 2021-07-22 (Crawled : 16:20) - ir.cyclerion.com
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: 14.44%
H: 0.0%
C: 0.0%
disease alzheimer phase 2 trial conference cy6463 alzheimer’s alzheimer's disease alzheimer's designation phase 2b
Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
Published: 2021-05-27 (Crawled : 21:00) - globenewswire.com
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: 1.25%
H: 4.92%
C: -0.31%
preclinical cy6463 pre-clinical
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.